ACCENDRA HEALTH INC/VA/

Listed Company

ACHCIK 0000075252NYSELarge AcceleratedWholesale-Medical, Dental & Hospital Equipment & SuppliesVirginiaFY ends Dec 31

Period

FY 2025

Revenue

$2.76B

Net Income

$-1.10B

Total Assets

$2.45B

Equity

$-460.98M

Shares Out

76.44M

Op. Cash Flow

$-101.79M

Business

Owens & Minor Inc. is a global healthcare solutions company that integrates product manufacturing, distribution support and technology services to serve healthcare providers and patients across care settings. The company offers medical and surgical supplies, infection-prevention products, proprietary branded goods, kitting and logistics, supplier management, analytics and clinical inventory programs, and home medical equipment and services for respiratory, sleep apnea, diabetes and other in-home care needs. It reports operations in two segments: Products & Healthcare Services and Patient Direct. Owens & Minor distributes products through hospitals, group purchasing organizations, third‑party distributors, direct sales, home health agencies, mail‑order and national pharmacy channels across North America, Europe, Asia, Australia and Latin America.

Summary from filing dated 2025-02-28

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net revenue	2,762	2,680	2,553	9,955	9,785
Cost of net revenue	1,473	1,400	1,336	8,129	8,272
Selling, general and administrative expenses	1,068	1,082	1,002	1,555	1,077
Goodwill impairment charge	0	307	0	0	—
Transaction breakage fee	80	—	—	—	—
Acquisition-related charges and intangible amortization	96	62	75	127	43
Exit and realignment charges, net	18	47	7	7	31
Total operating costs and expenses	2,735	2,898	2,419	—	—
Operating income (loss)	27	−218	133	143	368
Interest expense, net	107	108	117	—	—
Transaction financing fees, net	18	0	0	—	—
Other expense, net	4	5	1	3	3
(Loss) income from continuing operations before income taxes	−102	−330	15	11	277
Income tax provision	729,000	21	6	−11	55
(Loss) income from continuing operations, net of tax	−103	−351	9	—	—
Loss from discontinued operations, net of tax	998	12	50	—	—
Net loss	−1,101	−363	−41	22	222
(Loss) income from continuing operations, net of tax (in dollars per share)	−1.34	−4.57	0.12	0.3	3.05
Loss from discontinued operations, net of tax (in dollars per share)	−12.97	−0.16	−0.66	0	0
Net loss per common share Basic (in dollars per share)	−14.31	−4.73	−0.54	0.3	3.05
(Loss) income from continuing operations, net of tax (in dollars per share)	−1.34	−4.57	0.12	0.29	2.94
Loss from discontinued operations, net of tax (in dollars per share)	−12.97	−0.16	−0.65	0	0
Net loss per common share Diluted (in dollars per share)	−14.31	−4.73	−0.53	0.29	2.94

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	282	28	243	69	56
Accounts receivable, net	96	218	598	763	682
Inventories, net	74	68	1,100	1,300	1,500
Other current assets	96	82	151	129	89
Current assets held for sale - discontinued operations	—	1,625	—	—	—
Total current assets	548	2,021	2,103	2,295	2,322
Patient service equipment and other fixed assets, net	256	249	—	—	—
Operating lease assets	109	127	297	281	194
Goodwill	1,200	1,200	1,639	1,637	390
Intangible assets, net	136	210	362	445	210
Other assets, net	174	90	149	150	104
Noncurrent assets held for sale - discontinued operations	—	731	—	—	—
Total assets	2,452	4,656	5,093	5,386	3,537
Accounts payable	364	360	1,172	1,147	1,002
Accrued payroll and related liabilities	69	74	116	93	116
Current portion of long-term debt	250	43	207	18	—
Other current liabilities	264	295	397	308	226
Current liabilities held for sale - discontinued operations	—	1,081	—	—	—
Total current liabilities	947	1,852	1,892	1,566	1,344
Long-term debt, excluding current portion	1,800	1,798	1,891	2,483	948
Operating lease liabilities, excluding current portion	70	89	222	215	162
Deferred income taxes, net	—	19	42	61	35
Other liabilities	95	73	123	115	109
Noncurrent liabilities held for sale - discontinued operations	—	238	—	—	—
Total liabilities	2,913	4,070	4,169	4,441	2,598
Commitments and contingencies	—	—	—	—	—
Common stock, par value $2 per share; authorized - 200,000 shares; issued and outstanding - 76,388 shares and 77,199 shares	153	154	153	153	151
Paid-in capital	467	454	434	419	441
(Accumulated deficit) retained earnings	−1,080	27	369	410	388
Accumulated other comprehensive loss	−885,000	−49	−32	−36	−41
(Deficit) equity	−461	586	945	967	939
Total liabilities and (deficit) equity	2,452	4,656	5,093	5,386	3,537

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−1,101	−363	−41	—	—
Depreciation and amortization	215	181	210	229	91
Share-based compensation expense	13	17	14	21	25
Loss (gain) on extinguishment of debt	—	1	−4	—	—
Deferred income tax benefit	−18	−8	−6	−26	−30
Changes in operating lease right-of-use assets and lease liabilities	735,000	1	−57,000	353,000	1
Gain from sale and dispositions of patient service equipment	−27	−35	−35	−26	0
Accounts receivable, net	122	−4	−9	4	−2
Inventories	−7	−5	−5	167	−263
Accounts payable	6	67	5	14	4
Net change in other assets and liabilities	−57	−36	147	−92	692,000
Other, net	9	8	10	12	15
Cash (used for) provided by operating activities from discontinued operations	−256	18	404	—	—
Cash (used for) provided by operating activities	−102	161	741	—	—
Proceeds from P&HS sale	342	—	—	—	—
Cash sold with P&HS sale	−18	—	0	−1,685	0
Additions to patient service equipment and other fixed assets	−191	−170	−172	−158	−41
Proceeds from sale of patient service equipment	78	70	72	48	0
Additions to computer software	−10	−12	−6	−8	−9
Other, net	−2	15	−936,000	−2	−4
Cash used for investing activities from discontinued operations	−55	−18	−29	—	—
Cash provided by (used for) investing activities	144	−117	−137	−1,804	−54
Borrowings under amended Receivables Financing Agreement	—	1,466	476	1,022	0
Repayments under amended Receivables Financing Agreement	—	−1,466	−572	−1,156	0
Borrowings under Revolving Credit Facility	2,915	636	0	0	—
Repayments under Revolving Credit Facility	−2,711	−636	0	0	—
Repayments of debt	—	−244	−321	−5	−553
Repurchase of common stock	−10	—	—	—	—
Other, net	−3	−6	6	−43	−18
Cash used for financing activities from discontinued operations	−2	−18	−6	—	—
Cash provided by (used for) financing activities	188	−268	−417	1,497	−129
Effect of exchange rate changes on cash, cash equivalents and restricted cash	2	−901,000	613,000	−3	−4
Net increase (decrease) in cash, cash equivalents and restricted cash	233	−224	187	14	−62
Income taxes paid, net	12	6	−6	34	99
Interest paid	135	142	153	107	39
Unpaid purchases of patient service equipment and other fixed assets at end of period	74	85	77	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro